Citations

Clear

499 citation(s) found for "Tracy, PB".

Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation
Dukek, Brian A. , Kanipakam, Reddappa V.S.R., Ghoz, Hassan , Yab, Tracy C. , Giama, Nasra H., Onyirioha, Kristeen, Abdallah, Mohamed A., Burger, Kelli N. , Slettedahl, Seth W. , Smyrk, Thomas C. , Lewis, Jason T., Giakoumopoulos, Maria , Allawi, Hatim T. , Lidgard, Graham P. , Roberts, Lewis R. , Ahlquist, David A. , Kisiel, John B. , V S R Kanipakam, Reddappa, Ghoz, Hassan M, Berger, Calise K. , Foote, Patrick H. , Mahoney, Douglas W. , Roberts, Lewis R , Slettedahl, Seth W , Taylor, William R. , Abdallah, Mohamed A., Lewis, Jason T.

Mayo Clinic

Hepatology | August 31, 2018 | Volume: 69 | Issue: 3 | Pages: 1180-1192

10.1002/hep.30244 | PMID 30168613 Get It

Early detection improves hepatocellular carcinoma (HCC) outcomes, but better noninvasive surveillance tools are needed. We aimed to identify and validate methylated DNA markers (MDMs) for HCC detection. Reduced representation bisulfite sequencing was performed on DNA extracted from 18 HCC and 35 control tissues. Candidate MDMs were confirmed by quantitative methylation‐specific PCR in DNA from independent tissues (74 HCC, 29 controls). A phase I plasma pilot incorporated quantitative allele‐specific real‐time target and signal amplification assays on independent plasma‐extracted DNA from 21 HCC cases and 30 controls with cirrhosis. A phase II plasma study was then performed in 95 HCC cases, 51 controls with cirrhosis, and 98 healthy controls using target enrichment long‐probe quantitative amplified signal (TELQAS) assays. Recursive partitioning identified best MDM combinations. The entire MDM panel was statistically cross‐validated by randomly splitting the data 2:1 for training and testing. Random forest (rForest) regression models performed on the training set predicted disease status in the testing set; median areas under the receiver operating characteristics curve (AUCs; and 95% confidence interval [CI]) were reported after 500 iterations. In phase II, a six‐marker MDM panel (homeobox A1 [HOXA1], empty spiracles homeobox 1 [EMX1], AK055957 , endothelin‐converting enzyme 1 [ECE1], phosphofructokinase [PFKP], and C‐type lectin domain containing 11A [CLEC11A]) normalized by beta‐1,3‐galactosyltransferase 6 (B3GALT6) level yielded a best‐fit AUC of 0.96 (95% CI, 0.93‐0.99) with HCC sensitivity of 95% (88%‐98%) at specificity of 92% (86%‐96%). The panel detected 3 of 4 (75%) stage 0, 39 of 42 (93%) stage A, 13 of 14 (93%) stage B, 28 of 28 (100%) stage C, and 7 of 7 (100%) stage D HCCs. The AUC value for alpha‐fetoprotein (AFP) was 0.80 (0.74‐0.87) compared to 0.94 (0.9‐0.97) for the cross‐validated MDM panel (P < 0.0001). Conclusion : MDMs identified in this study proved to accurately detect HCC by plasma testing. Further optimization and clinical testing of this promising approach are indicated.
Abstract 230: Joint genome-wide association study of endometrial cancer and ovarian cancer identifies a novel genetic risk region at 14q23.3
Glubb, Dylan M., Lambrechts, Diether , Hall, Per, Trovik, Jone , Goode, Ellen L. , Fasching, Peter, Scott, Rodney J. , Auer, Paul L. , Tomlinson, Ian , Easton, Douglas F. , Thompson, Deborah J. , E2C2, BCAC, OCAC, ECAC, Lambrechts, Diether , Lambrechts, Diether , Lambrechts, Diether , O’Mara, Tracy A. , Buchanan, Daniel D. , Tham, Emma , Fasching, Peter, Dörk, Thilo , Milne, Roger L. , Giles, Graham G. , Perry, John Matthew , Vivo, Immaculata De , Spurdle, Amanda B. , E2C2, BCAC, OCAC, ECAC

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: 230-230

10.1158/1538-7445.am2018-230 Get It

Abstract Ovarian cancer is the most lethal gynecologic malignancy and the sixth most common cause of death from all cancer in women, with an estimated 140,000 deaths per year worldwide. Endometrial cancer (cancer of the uterine lining) is the most commonly diagnosed gynecologic cancer, ranking sixth in incident cancer in women. Ovarian and endometrial cancer share many epidemiologic, histopathologic, and tumor genetic characteristics. Meta-analyses of genome-wide association study (GWAS) datasets across etiologically related diseases have successfully been used to increase statistical power and identify novel genetic risk regions. We hypothesised that joint meta-analysis of ovarian and endometrial cancer GWAS datasets would identify novel genetic loci for both cancers. Following quality control, summary statistics for &gt;11 million genetic variants were available from the largest genome-wide association studies performed by the Ovarian Cancer Association Consortium (OCAC, Phelan et al., Nature Genetics 2017) and the Endometrial Cancer Association Consortium (ECAC, unpublished). A total of 35,312 cancer cases from all histologic subtypes (22,406 ovarian and 12,906 endometrial cancer cases) and 149,920 controls were included in the analysis. Summary statistics were combined using an inverse-variance, fixed-effects model in METAL and identified ten loci at genome-wide significance (P &lt; 5 x 10-8), of which one locus at 14q23.3 (rs4072776 combined OR 0.94; 95% CI 0.92-0.96; P = 8.0 x 10-9) had not been previously associated with the risk of either cancer. Integration with chromatin conformation data (RNAPolII HiChIP) from the Ishikawa endometrial cancer cell line suggests interaction between the risk signal and the promoter of FUT8. FUT8 encodes a fucosyltransferase and its expression has been implicated in breast, stomach, and melanoma and lung cancer. Interestingly, FUT8 is a downstream target regulated by the loss of PAX2 and mutated p53, which is the earliest known molecular aberration in the progression of the fallopian tissue epithelial to serous ovarian cancer. Further functional evaluation of the 14q23.3 risk region is required to determine the regulatory effect of genetic risk variants on FUT8. Future meta-analyses of datasets, stratifying results by histologic subtypes, will be undertaken. Citation Format: Tracy A. O'Mara, Dylan M. Glubb, Daniel D. Buchanan, Diether Lambrechts, Per Hall, Emma Tham, Jone Trovik, Ellen L. Goode, Peter Fasching, Thilo Dörk, Rodney J. Scott, Paul L. Auer, Roger L. Milne, Graham G. Giles, John Perry, Immaculata de Vivo, Ian Tomlinson, Douglas F. Easton, Deborah J. Thompson, Amanda B. Spurdle, E2C2, BCAC, OCAC, ECAC. Joint genome-wide association study of endometrial cancer and ovarian cancer identifies a novel genetic risk region at 14q23.3 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 230.
Core‐binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I‐CBFit)
Üstün, Celalettin , Pullarkat, Sheeja T. , Yeung, Cecilia C.S. , Broesby‐Olsen, Sigurd , Ohgami, Robert S. , Kim, Young , Vestergaard, Hanne , Chen, Dong , Kluin, Philip M., Dolan, Michelle, Mrózek, Krzysztof , Czuchlewski, David R., Horny, Hans‐Peter, George, Tracy I. , Kristensen, Thomas Kielsgaard , Ku, Nam K., Yi, Cecilia Arana , Møller, Michael , Marcucci, Guido , Hilberink, Jacobien R. , Pullarkat, Vinod , Shanley, Ryan , Kohlschmidt, Jessica, Coulombe, Janie , Salhotra, Amandeep , Soma, Lori , Cho, Christina , Hoermann, Gregor , Nakamura, Ryo , Deeg, Joachim, Bloomfield, Clara D. , Weisdorf, Daniel J. , Litzow, Mark R. , Valent, Peter , Huls, Gerwin , Yeung, Cecilia , Baughn, Linda, Chen, Dong , Møller, Michael Boe , Weisdorf, Dan , George, Tracy I , Arana Yi, Cecilia , Valent, Peter , Morgan, Elizabeth A. , Moodie, Erica E. M. , Sperr, Wolfgang R. , Baughn, Linda B. , Schiefer, Ana-Iris , Linden, Michael A. , Akin, Cem , Gotlib, Jason , Hornick, Jason L. , Nakamura, Ryo, Perales, Miguel‐Angel , Borthakur, Gautam

Mayo Clinic

Cancer Medicine | August 17, 2018 | Volume: 7 | Issue: 9 | Pages: 4447-4455

10.1002/cam4.1733 | PMID 30117318 Get It

AbstractBackgroundAlthough the prognosis of core‐binding factor (CBF) acute myeloid leukemia (AML) is better than other subtypes of AML, 30% of patients still relapse and may require allogeneic hematopoietic cell transplantation (alloHCT). However, there is no validated widely accepted scoring system to predict patient subsets with higher risk of relapse.MethodsEleven centers in the US and Europe evaluated 247 patients with t(8;21)(q22;q22).ResultsComplete remission (CR) rate was high (92.7%), yet relapse occurred in 27.1% of patients. A total of 24.7% of patients received alloHCT. The median disease‐free (DFS) and overall (OS) survival were 20.8 and 31.2 months, respectively. Age, KIT D816V mutated (11.3%) or nontested (36.4%) compared with KIT D816V wild type (52.5%), high white blood cell counts (WBC), and pseudodiploidy compared with hyper‐ or hypodiploidy were included in a scoring system (named I‐CBFit). DFS rate at 2 years was 76% for patients with a low‐risk I‐CBFit score compared with 36% for those with a high‐risk I‐CBFit score (P < 0.0001). Low‐ vs high‐risk OS at 2 years was 89% vs 51% (P < 0.0001).ConclusionsI‐CBFit composed of readily available risk factors can be useful to tailor the therapy of patients, especially for whom alloHCT is not need in CR1 (ie, patients with a low‐risk I‐CBFit score).
Human Plasma And Platelet Factor V Levels As Measured By Radioimmunoassay
Tracy, PB, Peterson, James M., Nesheim, ME, Katzmann, J A, Mann, Kenneth G.

Mayo Clinic

Thrombosis and Haemostasis | July 24, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1652216 Get It

Highly purified human Factor V was used for the development of a competitive double antibody radioimmunoassay (RIA) using 125I-human Factor V, burro anti-human Factor V antisera as the primary antibody and goat anti-burro antisera as the precipitating antibody. The standard curve allows the detection of as little as 20 ng of Factor V per ml of plasma. With this specific RIA for human Factor V, we have measured the level of Factor V in the plasma and platelets of normal individuals. The normal level of Factor V in plasma ranges from 4 to 14 μg per ml, with the average value equal to 7.0 ± 2.0 μg/ml (n = 64; 33 females; 31 males; 22 to 61 years of age). There appeared to be no correlation between antigen levels and age or sex. Factor V clotting assays were consistent with the RIA data for any given plasma preparation providing freshly drawn plasma was used in the bioassay. The bioassay data were quantitated based upon the specific activity of purified plasma Factor V; 1.7 units of Factor V equals 1 μg of protein. Plasma Factor V antigen levels were not affected by lyophilization of the plasma, prolonged storage of the plasma at -20°C or intentional conversion of the plasma to serum. The levels of Factor V present in washed human platelets were also determined using the RIA. Assay of washed platelets lysed in 0.2% Triton X-100 indicated that 0.6 to 0.85 μg of Factor V was present per 2.5 × 108 platelets (4400 to 6200 molecules of Factor V per platelet). This result is in marked contrast to our observations for the bovine system, where we found that bovine platelets possess approximately 400 to 800 molecules of Factor V per platelet, and plasma Factor V levels range from 30 to 50 μg per ml. In the bovine system, the platelets possess approximately 1% of the total Factor V present, while in human blood, the platelets possess as much as 10 to 15% of the total Factor V present.
The Coagulant Active Phospholipid(Pl) Content Of Prothrombin Complex Concentrates(Pcc) Is A Critical Determinant Of Their In Vivo Thrombogenicity
Giles, Alan R., Nesheim, ME, Tracy, Paula B., Hoogendoorn, H, Mann, K G

Mayo Clinic

Thrombosis and Haemostasis | July 24, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1651978 Get It

It has generally been assumed that the thrombogenicity of PCC relates to their invariable contamination by activated products of their component clotting factors. In earlier studies we demonstrated a lack of correlation between the activated clotting factor content ᶓ in vivo thrombogenicity of some PCC. In contrast, in vitro measurement of coagulant active PL content appeared to be a more reliable determinant of subsequent in vivo activity. In recent studies we have confirmed the presence of PL of known coagulant activity in PCC ᶓ studied its activity both in vitro ᶓ in vivo after its extraction from the parent PCC.PCCs were obtained from various agencies or prepared in our laboratory to a standard protocol either from fresh frozen plasma or plasma obtained from outdated platelet concentrates. Each was assayed for Xa (S-2222) ᶓ PL (thrombin generation assay with DAPA) ᶓ an index of thrombogenicity in vivo determined in a stasis model in rabbits. There was a significant correlation between the latter ᶓ PL (r=0.8727 p<0.01) but not Xa. Thin layer chromatography of an ethanol ether extract of the most thrombogenic PCC showed the presence of PL known to be coagulant active including Phospho- tidylserine ᶓ -choline. This extract retained full PL replacing activity in the DAPA assay in vitro but was non- thrombogenic in vivo. When, however, a highly purified preparation of Xa was added, in the same relative proportions as in the parent PCC, thrombogenicity in vivo was restored.It is concluded that the content of coagulant active PL is a critical determinant of the potential thrombogenicity of PCC in vivo. It appears to act in concert with Xa ᶓ conceivably, other serine proteases perhaps by protecting them from inactivation by AT III. This may explain why relatively “non-activated” PCCs may still be associated with thromboembolic complications.
Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use
Zakroysky, Pearl, Xiang, Qun, Goldberg, Anne C. , Robinson, Jennifer G. , Roger, Véronique L. , Wilson, Peter W.F. , Elassal, Joseph, Lee, L. Veronica, Wang, Tracy Y., Nanna, Michael G. , Návar, Ann Marie , Virani, Salim S. , Peterson, Eric D.

Mayo Clinic

JAMA Cardiology | June 13, 2018 | Volume: 3 | Issue: 8 | Pages: 739

10.1001/jamacardio.2018.1511 | PMID 29898219 Get It

TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.
Wood, William C., Makower, Della , Lively, Tracy , Saphner, Thomas J. , Keane, Maccon, Gomez, Henry Leonidas, Reddy, Pavan S. , Goggins, Timothy F., Toppmeyer, Deborah , Brufsky, Adam , Hayes, Daniel F. , Dees, Elizabeth Claire , Gómez, Henry , Brufsky, Adam M , Sparano, Joseph A. , Gray, Robert J. , Mayer, Ingrid A. , Goetz, Matthew P. , Pritchard, Kathleen I. , Geyer, Charles E. , Olson, John A. , Sledge, George W.

Mayo Clinic

Journal of Clinical Oncology | June 7, 2018 | Volume: 36 | Issue: 18_suppl | Pages: LBA1-LBA1

10.1200/jco.2018.36.18_suppl.lba1 Get It

LBA1 Background: In hormone receptor (HR)-positive, HER2-negative, axillary node (AN)-negative breast cancer, the 21-gene expression assay (Oncotype DX Recurrence Score [RS]) is prognostic for distant recurrence, prognostic for low recurrence with endocrine therapy alone if low (0-10), and predictive of chemotherapy benefit if high (26 or higher). We performed a prospective, randomized trial of endocrine therapy (ET) versus chemoendocrine therapy (CET) in women with a mid-range RS of 11-25. Methods: Eligibility criteria included women 18-75 years of age with HR-positive, HER2-negative, axillary node (AN)-negative breast cancer and tumors 1.1-5.0 cm in size (or 0.6-1.0 cm and int/high grade) and agreed to have chemotherapy assigned or randomized based on the RS. Women with a mid-range RS (11-25) were randomized to receive ET or CET. The primary endpoint was invasive disease-free survival (iDFS), and the trial was designed to show non-inferiority for ET alone by not rejecting equality (hazard ratio [HR] margin up to 1.322 for omission of chemotherapy, 1-sided type I error rate 10%, type II error rate 5%). The target sample size was adjusted to compensate for non-adherence to randomized treatment, and the protocol-specified final analysis was triggered after 835 iDFS events. Results: Of the 10,253 eligible women enrolled between 4/7/06-10/6/10, 6711 (65.5%) had a RS of 11-25 and adequate information. There were 836 iDFS events at final analysis with a median followup of 90 months. ET was non-inferior to CET for iDFS (HR 1.08, 95% confidence intervals [CI] 0.94, 1.24, p=0.26) in the intention-to-treat (ITT) population. ET was also non-inferior for distant recurrence-free interval (DRFI; HR 1.03, p=0.80), recurrence-free interval (RFI; HR 1.12, p=0.28), and overall survival (OS; HR 0.97, p=0.80). Nine year rates were similar for iDFS (83.3% vs. 84.3%), DRFI (94.5% vs. 95.0%), RFI (92.2% vs. 92.9%), and OS (93.9% vs. 93.8%). Recurrence accounted for 338 (41.6%) the first iDFS event, of which 199 (23.8%) were distant recurrences. Treatment interaction tests were significant for age (iDFS p=0.03; RFI p= 0.02), but not menopause, tumor size, grade, or RS (continuous or RS 11-15, 16-20, 21-25). Conclusions: In women with HR-positive, HER2-negative, AN-negative breast cancer and a RS of 11-25, adjuvant ET was not inferior to CET in the ITT analysis. (Funded by NCI, BCRF, and Komen Foundation.) Clinical trial information: NCT00310180.
Continual near-infrared spectroscopy monitoring in the injured lower limb and acute compartment syndrome
Shuler, Michael S. , Roskosky, Mellisa , Kinsey, Tracy L. , Glaser, Dale , Reisman, W. Michael , Ogburn, C., Yeoman, C M, Wanderman, Nathan , Freedman, Brett A.

Mayo Clinic

The Bone & Joint Journal | June 7, 2018 | Volume: 100-B | Issue: 6 | Pages: 787-797

10.1302/0301-620x.100b6.bjj-2017-0736.r3 | PMID 29855235 Get It

AimsThe aim of this study was to evaluate near-infrared spectroscopy (NIRS) as a continuous, non-invasive monitor for acute compartment syndrome (ACS).Patients and MethodsNIRS sensors were placed on 86 patients with, and 23 without (controls), severe leg injury. NIRS values were recorded for up to 48 hours. Longitudinal data were analyzed using summary and graphical methods, bivariate comparisons, and multivariable multilevel modelling.ResultsMean NIRS values in the anterior, lateral, superficial posterior, and deep posterior compartments were between 72% and 78% in injured legs, between 69% and 72% in uninjured legs, and between 71% and 73% in bilaterally uninjured legs. In patients without ACS, the values were typically > 3% higher in injured compartments. All seven limbs with ACS had at least one compartment where NIRS values were 3% or more below a reference uninjured control compartment. Missing data were encountered in many instances.ConclusionNIRS oximetry might be used to aid the assessment and management of patients with ACS. Sustained hyperaemia is consistent with the absence of ACS in injured legs. Loss of the hyperaemic differential warrants heightened surveillance. NIRS values in at least one injured compartment(s) were > 3% below the uninjured contralateral compartment(s) in all seven patients with ACS. Additional interventional studies are required to validate the use of NIRS for ACS monitoring. Cite this article: Bone Joint J 2018;100-B:787–97.
Detection of Gastric Cancer with Novel Methylated DNA Markers: Discovery, Tissue Validation, and Pilot Testing in Plasma
Anderson, Bradley W., Suh, Yun‐Suhk , Choi, Boram , Lee, Hyuk‐Joon , Yab, Tracy C. , Dukek, Brian A. , Cao, Xiaoming , Devens, Mary E., Boardman, Lisa A., Slettedahl, Seth W. , Allawi, Hatim T. , Lidgard, Graham P. , Smyrk, Thomas C. , Yang, Han‐Kwang , Ahlquist, David A. , Berger, Calise K. , Foote, Patrick H. , Kisiel, John B. , Mahoney, Douglas W. , Slettedahl, Seth W , Taylor, William R. , Boardman, Lisa A.

Mayo Clinic

Clinical Cancer Research | May 29, 2018 | Volume: 24 | Issue: 22 | Pages: 5724-5734

10.1158/1078-0432.ccr-17-3364 | PMID 29844130 Get It

Abstract Purpose: Gastric adenocarcinoma is the third most common cause of cancer mortality worldwide. Accurate and affordable noninvasive detection methods have potential value for screening and surveillance. Herein, we identify novel methylated DNA markers (MDM) for gastric adenocarcinoma, validate their discrimination for gastric adenocarcinoma in tissues from geographically separate cohorts, explore marker acquisition through the oncogenic cascade, and describe distributions of candidate MDMs in plasma from gastric adenocarcinoma cases and normal controls. Experimental Design: Following discovery by unbiased whole-methylome sequencing, candidate MDMs were validated by blinded methylation-specific PCR in archival case–control tissues from U.S. and South Korean patients. Top MDMs were then assayed by an analytically sensitive method (quantitative real-time allele-specific target and signal amplification) in a blinded pilot study on archival plasma from gastric adenocarcinoma cases and normal controls. Results: Whole-methylome discovery yielded novel and highly discriminant candidate MDMs. In tissue, a panel of candidate MDMs detected gastric adenocarcinoma in 92% to 100% of U.S. and South Korean cohorts at 100% specificity. Levels of most MDMs increased progressively from normal mucosa through metaplasia, adenoma, and gastric adenocarcinoma with variation in points of greatest marker acquisition. In plasma, a 3-marker panel (ELMO1, ZNF569, C13orf18) detected 86% (95% CI, 71–95) of gastric adenocarcinomas at 95% specificity. Conclusions: Novel MDMs appear to accurately discriminate gastric adenocarcinoma from normal controls in both tissue and plasma. The point of aberrant methylation during oncogenesis varies by MDM, which may have relevance to marker selection in clinical applications. Further exploration of these MDMs for gastric adenocarcinoma screening and surveillance is warranted. Clin Cancer Res; 24(22); 5724–34. ©2018 AACR.
Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry
Wang, Tracy Y., Mi, Xiaojuan, Louie, Michael J. , Lee, L. Veronica, Goldberg, Anne C. , Roger, Véronique L. , Robinson, Jennifer G. , Nanna, Michael G. , Návar, Ann Marie , Virani, Salim S. , Peterson, Eric D.

Mayo Clinic

Journal of the American Heart Association | May 8, 2018 | Volume: 7 | Issue: 10 | Pages: No page available

10.1161/jaha.118.008546 | PMID 29739801 Get It

Background Current statin use and symptoms among older adults in routine community practice have not been well characterized since the release of the 2013 American College of Cardiology/American Heart Association guideline. Methods and Results We compared statin use and dosing between adults >75 and ≤75 years old who were eligible for primary or secondary prevention statin use without considering guideline‐recommended age criteria. The patients were treated at 138 US practices in the Patient and Provider Assessment of Lipid Management (PALM) registry in 2015. Patient surveys also evaluated reported symptoms while taking statins. Multivariable logistic regression models examined the association between older age and statin use and dosing. Among 6717 people enrolled, 1704 (25%) were >75 years old. For primary prevention, use of any statin or high‐dose statin did not vary by age group: any statin, 62.6% in those >75 years old versus 63.1% in those ≤75 years old ( P =0.83); high‐dose statin, 10.2% versus 12.3% in the same groups ( P =0.14). For secondary prevention, older patients were slightly less likely to receive any statin (80.1% versus 84.2% [ P =0.003]; adjusted odds ratio, 0.81; 95% confidence interval, 0.66–1.01 [ P =0.06]), but were much less likely to receive a high‐intensity statin (23.5% versus 36.2% [ P <0.0001]; adjusted odds ratio, 0.54; 95% confidence interval, 0.45–0.65 [ P =0.0001]). Among current statin users, older patients were slightly less likely to report any symptoms (41.3% versus 46.6%; P =0.003) or myalgias (27.3% versus 33.3%; P <0.001). Conclusions Overall use of statins was similar for primary prevention in those aged >75 years versus younger patients, yet older patients were less likely to receive high‐intensity statins for secondary prevention. Statins appear to be similarly tolerated in older and younger adults.